GlassScriptPhysician profile
Carlos A Rollhauser
NPI 1407933658
$144,318.13
in general payments reported to CMS, 2019-2025
58 companies · $33K in 2025
The $33K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58K · 2020: $12K · 2021: $816 · 2022: $16K · 2023: $7,548 · 2024: $17K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Food and Beverage: $8,705 · Travel and Lodging: $6,729 · Education: $58.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $42,759.00 |
| Food and Beverage | $8,704.69 |
| Travel and Lodging | $6,729.15 |
| Education | $58.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $100,252.16 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $35,718.31 | 2019-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $1,103.49 | 2019-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $900.56 | 2019-2025 | |
| Celgene Corporation | $539.01 | 2021-2024 | Zeposia |
| Pfizer INC. | $477.65 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $456.05 | 2019-2024 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $327.10 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $311.30 | 2022-2025 | Ibsrela |
| Daiichi Sankyo INC. | $291.22 | 2019-2025 | Injectafer |
| Madrigal Pharmaceuticals | $266.25 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $252.69 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $211.14 | 2019-2023 | Rebyota |
| Phathom Pharmaceuticals, INC. | $199.93 | 2023-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $192.08 | 2019-2025 | Ocaliva |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $188.46 | 2023-2025 | Omvoh |
| Evoke Pharma, INC. | $164.67 | 2022-2024 | Gimoti |
| Amgen INC. | $163.16 | 2021-2025 | Uplizna, Amjevita, Avsola |
| Celltrion USA INC. | $161.18 | 2023-2025 | Vegzelma, Yuflyma, Zymfentra |
| Merck Sharp & Dohme LLC | $156.57 | 2019-2024 | Dificid |
| Braintree Laboratories, INC. | $146.84 | 2020-2025 | Suflave, Sutab |
| Aimmune Therapeutics, INC. | $146.56 | 2024-2025 | Zenpep |
| Intra-Sana Laboratories | $111.27 | 2022 | |
| Alnylam Pharmaceuticals INC. | $103.49 | 2021-2024 | Givlaari |
| Nestle Healthcare Nutrition INC. | $101.71 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $100.47 | 2019-2021 | |
| Redhill Biopharma INC. | $98.62 | 2020-2023 | Movantik, Aemcolo, Talicia |
| Ucb, INC. | $96.76 | 2019-2020 | |
| Alcresta Therapeutics, INC. | $96.35 | 2022 | |
| Organon LLC | $87.75 | 2022-2025 | Hadlima, Renflexis |
| Medtronic, INC. | $69.04 | 2023 | Gi Genius, Prodigi |
| Sandoz INC. | $60.64 | 2024-2025 | Hyrimoz |
| Allergan, INC. | $59.57 | 2020 | |
| Novo Nordisk INC | $58.38 | 2025 | Wegovy |
| Shionogi INC | $57.57 | 2019 | |
| Pinnacle Biologics, INC | $50.74 | 2024 | Photofrin |
| Enterra Medical, INC. | $46.28 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.16 | 2023 | Cyltezo |
| Vbi Vaccine (Delaware) INC. | $39.03 | 2022-2023 | Prehevbrio |
| Pharmacosmos Therapeutics INC. | $35.89 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $34.47 | 2024 | Iqirvo |
| Teva Pharmaceuticals USA, INC. | $33.23 | 2024 | Simlandi |
| Boston Scientific Corporation | $32.41 | 2019 | |
| Mallinckrodt Hospital Products INC. | $28.23 | 2024 | Terlivaz |
| Qol Medical, LLC | $27.34 | 2025 | Sucraid |
| Cook Medical LLC | $24.99 | 2019-2020 | |
| Ethicon US, LLC | $24.43 | 2020 | |
| Mauna Kea Technologies, INC. | $23.95 | 2025 | |
| Fresenius Kabi USA, LLC | $22.38 | 2023 | Idacio |
| Endogastric Solutions, INC | $21.22 | 2023 | Esophyx |
| Olympus America INC. | $18.48 | 2022 | |
| Ambu INC. | $16.56 | 2020 | |
| Endo Pharmaceuticals INC. | $15.22 | 2019 | |
| Capsovision, INC. | $15.20 | 2024 | Capsocam Plus |
| Axonics, INC. | $14.64 | 2024 | Axonics |
| Amag Pharmaceuticals, INC. | $12.99 | 2022 | |
| Echosens North America, INC. | $10.12 | 2025 | Fibroscan |
| Romark Laboratories, Lc | $3.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Rollhauser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.